Treatment of Inflammatory Demyelinating Neuropathies

Journal of Clinical Neuromuscular Disease

Volumn 1, Issue 1, 1999, Pages 21-31

  Smith, A Gordon ^a   Bromberg, Mark B ^a  

^a UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 0346365971     PISSN: 15220443     EISSN: None     Source Type: Journal    
DOI: 10.1097/00131402-199909000-00007     Document Type: Review

References (81)

1. Griffin J, Li C, Ho T, et al. Pathology of the motor-sensory axonal Guillain-Barré syndrome. Ann Neurol 1996;39:17-28.
2. Ropper A, Wijkicks E, Truax B. Guillain-Barré Syndrome. Philadelphia, PA: FA Davis, 1991.
3. Ropper A. The Guillain-Barré syndrome. N Engl J Med 1992; 326:1130-1136.
4. Albers J, Kelly J. Acquired inflammatory demyelinating polyneuropathies: clinical and electrodiagnostic features. Muscle Nerve 1989;12:435-451.
5. Alam A, Chaudhury V, Cornblath D. Electrophysiological studies in the Guillain-Barré syndrome: distinguishing subtypes by published criteria. Muscle Nerve 1998;21:1275-1279.
6. Hadden R, Cornblath D, Hughes R, et al. Electrophysiological classification of Guillain-Barré syndrome: clinical associations and outcome. Ann Neurol 1998;44:780-788.
7. Fisher C. An unusual variant of acute idiopathic polyneuritis (syndrome of ophthalmoplcgia, ataxia and areflexia). N Engl J Med 1956;255:57-65.
8. McKhann G, Cornblath D, Griffin J, et al. Acute motor axonal neuropathy: a frequent cause of acute flaccid paralysis in China. Ann Neurol 1993;33:333-342.
9. Rees J, Soudain S, Gregson N, Hughes R. Campylobacter jejuni infection and Guillain-Barré syndrome. N Engl J Med 1995;333: 1373-1379.
10. Oomes P, Jacobs B, Hazenberg M, Banffer J, van der Meche F. Anti-GM1 antibodies and Campylobacter bacteria in Guillain-Barré syndrome: evidence of molecular mimicry. Ann Neurol 1995;38:170-175.
11. Chiba A, Kusunoki S, Obata H, Machinami R, Kanazawa I. Scrum anti-GQlb IgG antibody is associated with ophthalmoplegia in Miller Fisher syndrome and Guillain-Barré syndrome: clinical and immunohistochemical studies. Neurology 1993;43:911-917.
12. Kornberg A, Pestronk A, Blume G, Lopate G, Yue J, Hahn A. Selective staining of the cerebellar molecular layer by serum IgG in Miller Fisher and related syndromes. Neurology 1996;47:1317-1320.
13. The Guillain-Barré Syndrome Study Group. Plasmapheresis and acute Guillain-Barré syndrome. Neurology 1985;35:1096-1104.
14. The French Cooperative Group on Plasma Exchange in Guillain Barré Syndrome. Efficiency of plasma exchange in Guillain-Barré syndrome: role of replacement fluids. Ann Neurol 1987;22:753-761.
15. The French Cooperative Group on Plasma Exchange in Guillain-Barré Syndrome. Plasma exchange in Guillain-Barré syndrome: one year follow-up. Ann Neurol 1992;32:94-97.
16. The French Cooperative Group on Plasma Exchange in Guillain-Barré Syndrome. Appropriate number of plasma exchanges in Guillain-Barré syndrome. Ann Neurol 1997;41:298-306.
17. Van der Meche F, Schmitz P, Dutch Guillain-Barré Group. A randomized trial comparing intravenous immune globulin and plasma exchange in Guillain-Barré syndrome. N Engl J Med 1992;326:1123-1129.
18. McKhann G, Griffin J, Cornblath D, et al. Plasmapheresis and Guillain-Barré syndrome: analysis of prognostic factors and the effect of plasmapheresis. Ann Neurol 1988;23:347-353.
19. Bril V, Ilse W, Pearce R, Dhanani A, Sutton D, Kong K. Pilot trial of immunoglobulin versus plasma exchange in patients with Guillain-Barré syndrome. Neurology 1996;46:100-103.
20. Plasma Exchange/Sandoglobulin Guillain Barré Syndrome Trial Group. Randomized trial of plasma exchange, intravenous immunoglobulin, and combined treatments in Guillain Barré syndrome. Lancet 1997;349:225-230.
21. Ropper A, Albers J, Addison R. Limited relapse in Guillain-Barré syndrome after plasma exchange. Arch Neurol 1988;45:314-315.
22. Rudnicki S, Vriesendorp F, Koski C, Mayer R. Electrophysiologic studies in the Guillain-Barré syndrome: effects of plasma exchange and antibody rebound. Muscle Nerve 1992;15:57-62.
23. Castro L, Ropper A. Human immune globulin infusion in Guillain-Barré syndrome: worsening during and after treatment. Neurology 1993;43:1034-1036.
24. Irani D, Cornblath D, Chaudhury V, Borel C, Hanley D. Relapse in Guillain-Barrc syndrome after treatment with human immune globulin. Neurology 1993;43:872-875.
25. Hughes R, Kadlubowski M, Hufschmidt A. Treatment of acute inflammatory polyneuropathy. Ann Neurol 1981;9(suppl):125-133.
26. Hughes R, Newsome-Davis J, Perkin G, Pierce J. Controlled trial of prednisolone in acute polyneuropathy. Lancet 1978;2: 750-753.
27. Guillain Barré Study Steroid Trial Group. Double-blind trial of intravenous methylprednisolone in Guillain-Barré syndrome. Lancet 1993;341:586-590.
28. The Dutch Guillain Barré Study Group. Treatment of Guillain-Barré syndrome with high-dose immune globulins combined with methylprednisolone: a pilot study. Ann Neurol 1994;35: 749-752.
29. Gurses N, Uyasal S, Centinkaya F, Islek I, Kalayci A. Intravenous immunoglobulin in children with Guillain-Barré syndrome. Scand J Infect Dis 1995;27:241-243.
30. Bradshaw D, Jones H. Guillain-Barré syndrome in children: clinical course, electrodiagnosis, and prognosis. Muscle Nerve 1992;15:500-506.
31. Reisin R, Pociecha J, Rodriquez E, Masssaro M, Arroyo H, Fejerman N. Severe Guillain-Barré syndrome in childhood treated with human immune globulin. Pediatr Neurol 1996;14:308-312.
32. Storgion S, Igarashi M, May W, Stidham G. Plasmapheresis for Guillain-Barré syndrome. Pediatr Neurol 1989;5:389-390.
33. Lamont P, Johnston H, Berdoukas V. Plasmapheresis in children with Guillain-Barré syndrome. Neurology 1991;41:1928-1931.
34. Epstein M, Sladky J. The role of plasmapheresis in childhood Guillain-Barré syndrome. Ann Neurol 1990;28:65-69.
35. Ho T, Li C, Cornblath D, Gao C, Asbury A, Griffin J, McKhann G. Patterns of recovery in the Guillain-Barré syndromes. Neurology 1997;48:695-700.
36. Visser L, Van Der Meche P, Van Doom P, et al. Guillain-Barré syndrome without sensory loss (acute motor neuropathy): a sub-group with specific clinical, electrodiagnostic and laboratory features. Brain 1995;118:841-847.
37. Feasby T, Gilbert J, Brown W. An acute axonal form of Guillain-Barré polyneuropathy. Brain 1986;109:1115-1126.
38. Arakawa Y, Yoshimura M, Kobayashi S, et al. The use of intravenous immunoglobulin in Miller Fisher syndrome. Brain Dev 1993;15:231-233.
39. Littlewood R, Bajada S. Successful plasmapheresis in the Miller Fisher syndrome. BMJ 1981;282:778.
40. Zifko U, Drlicek M, Grisold W. High dose immunoglobulin therapy is effective in the Miller Fisher syndrome. J Neurol 1994; 241:178-179.
41. Yuki N. Tryptophan-immobilized column adsorbs immunoglobulin G anti-GQ1b antibody from Fisher's syndrome: a new approach to treatment. Neurology 1996;46:1644-1651.
42. Ohtsuka K, Nakamura Y, Tagawa Y, Nobuhiro N. Immunoadsorption therapy for Fisher syndrome associated with IgG anti-GQ1b antibody. Am J Ophthalmol 1998;125:403-406.
43. Chida K, Takase S, Itoyama Y. Development of facial palsy during immunoadsorption plasmapheresis in Miller Fisher syndrome: a clinical report of two cases. J Neurol Neurosurg Psychiatry 1998;64:399-401.
44. Ad Hoc Subcommittee of the American Academy of Neurology AIDS Task Force. Research criteria for diagnosis of chronic inflammatory demyelinating polyneuropathy (CIDP). Neurology 1991;41:617-618.
45. Bromberg M. Comparison of electrodiagnostic criteria for primary demyelination in chronic polyneuropathy. Muscle Nerve 1991;14:968-976.
46. Dyck P, Dyck J, Chalk C. The 10 P's: a mnemonic helpful in characterization of differential diagnosis of peripheral neuropathy. Neurology 1992;41:14-18.
47. Chroni E, Hall S, Hughes R. Chronic relapsing axonal neuropathy: a first case report. Ann Neurol 1995;37:112-115.
48. Uncini A, Sabetelli M, Mignogna T, Lugaresi A, Liguori R, Montagna R. Chronic progressive steroid responsive axonal polyneuropathy: a CIDP variant or a primary axonal disorder. Muscle Nerve 1996;19:365-371.
49. Dyck P, O'Brien P, Oviatt K, et al. Prednisone improves chronic inflammatory demyelinating polyradiculoneuropathy more than no treatment. Ann Neurol 1982;11:136-141.
50. Barohn RJ, Kissel JT, Warmolts JR, Mendell JR. Chronic inflammatory demyelinating polyradiculoneuropathy, clinical characteristics, course, and recommendations for diagnostic criteria. Arch Neurol 1989;46:878-884.
51. Simmons Z, Albers J, Bromberg M, Feldman E. Presentation and initial clinical course in patients with chronic inflammatory demyelinating polyradiculoneuropathy: comparison of patients without and with monoclonal gammopathy. Neurology 1993;43: 2202-2209.
52. Axelrod L. Glucocorticoid therapy. Medicine 1976;55:39-65.
53. Dyck P, Daube J, O'Brien P, et al. Plasma exchange in chronic inflammatory demyelinating polyradiculoneuropathy. N Engl J Med 1986;314:461-465.
54. Hahn A, Bolton C, Pillay N, et al. Plasma-exchange therapy in chronic inflammatory demyelinating polyneuropathy: a double-blind, sham-controlled, cross-over study. Brain 1996;119:1055-1066.
55. Donofrio P, Tandan R, Albers J. Plasma exchange in chronic inflammatory demyelinating polyradiculoneuropathy. Muscle Nerve 1985;8:321-327.
56. Hahn A, Bolton C, Zochodne D, Feasby T. Intravenous immunoglobulin treatment in chronic inflammatory demyelinating polyneuropathy: a double-blind, placebo-controlled, cross-over study. Brain 1996;119:1067-1077.
57. van Doom P, Brand A, Strengers P, Meulstee J, Vermeulen M. High-dose intravenous immunoglobulin treatment in chronic inflammatory demyelinating polyneuropathy: a double-blind, placebo-controlled, crossover study. Neurology 1990;40:209-212.
58. Facd J, Day B, Pollock M, Taylor P, Nukada H, Hammond-Tooke G. High-dose intravenous immunoglobulin in chronic inflammatory demyelinating polyneuropathy. J Neurol Neurosurg Psychiatry 1989;39:422-425.
59. Cornblath D, Chaudhury V, Griffin J. Treatment of chronic inflammatory demyelinating polyneuropathy with intravenous immunoglobulin. Ann Neurol 1991;30:104-106.
60. Dyck P, Litchy W, Kratz K, et al. A plasma exchange versus immune globulin infusion trial in chronic inflammatory demyelinating polyradiculoneuropathy. Ann Neurol 1994;36:838-845.
61. van Doorn P, Vermeulen M, Brand A, Mulder P, Busch H. Intravenous immunoglobulin treatment in patients with chronic inflammatory demyelinating polyneuropathy: clinical and laboratory characteristics associated with improvement. Arch Neurol 1991;48:217-220.
62. Vermeulen M, van Doom P, Brand A, Strengers P, Jennekens F, Busch H. Intravenous immunoglobulin treatment in patients with chronic inflammatory demyelinating polyneuropathy: a double blind, placebo controlled study. J Neurol Neurosurg Psychiatry 1993;56:36-39.
63. Palace J, Newsom-Davis J, Lecky B, the Myasthenia Gravis Study Group. A randomized double-blind trial of prednisolone alone or with azathioprine in myasthenia gravis. Neurology 1998; 50:1778-1783.
64. Pentland B, Adams G, Mawdsley C. Chronic idiopathic polyneuropathy treated with azathioprine. J Neurol Neurosurg Psychiatry 1982;46:866-869.
65. Gorson K, Ropper A, Clark B, Dew RB, Simovic D, Allam G. Treatment of chronic inflammatory demyelinating polyneuropathy with interferon-α2a. Neurology 1998;50:84-87.
66. Sabatelli M, Mignogna T, Lippi G, Milone M, Di Lazzaro V, Tonali P. Interferon-α may benefit steroid unresponsive inflammatory demyelinating polyneuropathy. J Neurol Neurosurg Psychiatry 1995;58:638-639.
67. Gorson K, Allam G, Simovic D, Ropper A. Improvement following interferon-alpha 2A in chronic inflammatory demyelinating polyneuropathy. Neurology 1997;48:777-780.
68. Gorson K, Allam G, Ropper A. Chronic inflammatory demyelinating polyneuropathy: clinical features and response to treatment in 67 consecutive patients with and without a monoclonal gammopathy. Neurology 1997;48:321-328.
69. Chaudhury P, Thompson N, Hughes R. Improvement following Interferon beta in chronic inflammatory demyelinating polyradiculoneuropathy. J Neurol 1994;242:252-253.
70. Hodgkinson S, Pollard J, McLeod J. Cyclosporin A in the treatment of chronic demyelinating polyradiculoneuropathy. J Neurol Neurosurg Psychiatry 1990;53:327-330.
71. Koklin S, Nahman N, Mendell J. Chronic nephrotoxicity complicating cyclosporine treatment of chronic inflammatory demyelinating polyradiculoneuropathy. Neurology 1987;37:147-149.
72. Mahattanakul W, Crawford T, Griffin J, Goldstein J, Cornblath D. Treatment of chronic inflammatory demyelinating polyneuropathy with cyclosporin-A. J Neurol Neurosurg Psychiatry 1996; 60:185-187.
73. Molenaar D, van Doom P, Vermeulen M. Pulsed high dose dexamethasone treatment in chronic inflammatory demyelinating polyneuropathy: a pilot study. J Neurol Neurosurg Psychiatry 1997;62:388-390.
74. Rosenberg N, Lacy J, Kennaugh R, Holers M, Neville H, Kotzin B. Treatment of refractory chronic demyelinating polyneuropathy with lymphoid irradiation. Muscle Nerve 1985;8:223-232.
75. Simmons Z, Wald J, Albers J. Chronic inflammatory demyelinating polyradiculoneuropathy in children. I: presentation, electro-diagnostic studies, and initial clinical course, with comparison to adults. Muscle Nerve 1997;20:1008-1015.
76. Simmons Z, Wald J, Albers J. Chronic inflammatory demyelinating polyradiculoneuropathy in children. II: long term follow-up with comparison to adults. Muscle Nerve 1997;20:1569-1575.
77. Vattaikorumakankav V, Kandt R, Lewis D, DeLong G. Chronic inflammatory demyelinating polyradiculoneuropathy of childhood: treatment with high-dose intravenous immunoglobulin. Neurology 1991;41:828-830.
78. Simmons Z, Albers J, Bromberg M, Feldman E. Long-term follow-up of patients with chronic inflammatory demyelinating polyradiculoneuropathy, without and with monoclonal gammopathy. Brain 1995;118:359-368.
79. Bromberg M, Feldman E, Jaradeh S, Albers J. Prognosis in long-term immunosuppressive treatment of refractory chronic inflammatory demyelinating polyradiculoneuropathy. J Clin Epidemiol 1992;45:47-52.
80. Bromberg M, Feldman E, Albers J. Chronic inflammatory demyelinating polyradiculoneuropathy: comparison of patients with and without an associated monoclonal gammopathy. Neurology 1992;42:1157-1163.
81. Simmons Z, Wald J, Albers J, Feldman E. The natural history of a 'benign' rib lesion in a patient with a demyelinating polyneuropathy and an unusual variant of POEMS syndrome. Muscle Nerve 1994;17:1055-1059.